✦ LIBER ✦

44LBA Results of a phase I clinical trial of MGN1703, a novel TLR9-agonist, in patients with metastatic malignancies

✍ Scribed by M. Weihrauch; M. Schmidt; M. Tschaika; H. Richly; M.S. von Bergwelt-Baildon; U. Hacker; A. Shimabokuro-Vornhagen; B. Wittig; M.E. Scheulen

Book ID: 119600821
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 65 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(09)72079-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

47 Immunotherapy with the toll-like rece

47 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - safety results of a clinical phase I study

✍ M.R. Weihrauch; H. Richly; M.S. von Bergwelt-Baildon; U. Hacker; A. Shimabukuro- 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

46 Immunotherapy with the toll-like rece

46 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study

✍ M.R. Weihrauch; M.S. von Bergwelt-Baildon; U. Hacker; H. Richly; U. Holtick; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

409 POSTER A Phase I clinical trial of t

409 POSTER A Phase I clinical trial of the oral PPAR gamma agonist, CS-7017 in patients with advanced malignancies

✍ M.J. Pishvaian; A. Wagner; J. Deeken; A.R. He; J. Hwang; S. Malik; I. Cotarla; G 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Outpatient combination chemoimmunotherap

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial

✍ Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## BACKGROUND. Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma. ## METHODS. Nineteen patients were treated with intravenous cispl

A phase I trial of dactinomycin intraven

A phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

✍ Martin S. Blumenreich; Thomas M. Woodcock; Stephen P. Richman; Mariesa K. Jones; 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 3 views

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered

A phase I pharmacokinetic trial of zilas

A phase I pharmacokinetic trial of zilascorb(2H) in patients with advanced malignancies

✍ Semb, KA; Aamdal, S; Klem, B; Osmundsen, K; Bibow, K; Pronova, 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 173 KB